Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 28 citing Schwartz: Relation of characteristics of metabolic syndrome to short-term prognosis and effects.... (0.09 sec) 

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and …

- lipidgeneticsclinic.ca [PDF] 
P Deedwania, P Barter, R Carmena, JC … - The Lancet, 2006 - Elsevier
The TNT study was a prospective, double blind, parallel-group trial done at 256
sites in 14 countries between April, 1998, and August, 2004, with a median
follow-up of 4·9 years. 10 001 patients were enrolled aged 35–75 years ...
Cited by 108 - Related articles - All 11 versions

The novel adipocytokine visfatin exerts direct cardioprotective effects


SY Lim, SM Davidson, AJ Paramanathan, CC … - J Cell Mol Med, 2008 - interscience.wiley.com
Visfatin is an adipocytokine capable of mimicking the glucose-lowering effects
of insulin and activating the pro-survival kinases phosphatidylinositol-3-OH
kinase (PI3K)-protein kinase B (Akt) and mitogen-activated protein kinase ...
Cited by 14 - Related articles - All 3 versions

Platelet resistance to the anti-aggregating agents in the insulin resistant states


G Anfossi, I Russo, M Trovati - Current Diabetes Reviews, 2006 - ingentaconnect.com
Page 1. Current Diabetes Reviews, 2006, 2, 409-430 409 1573-3998/06
$50.00+.00 © 2006 Bentham Science Publishers Ltd. Platelet Resistance ...
Cited by 6 - Related articles - BL Direct - All 2 versions

Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical …


KA Bybee, JH Lee, JH O'Keefe - Current Medical Research and Opinion®, 2008 - informahealthcare.com
Kevin a. Bybee, John h. Lee and James h. O'Keefe ... Saint Luke's Mid America
Heart Institute and University of Missouri-Kansas City, Kansas City, MO, USA
... Address for correspondence: James H. O'Keefe, MD, 4330 Wornall Rd, Ste ...
Cited by 6 - Related articles - All 5 versions

Preconditioning and postconditioning: new strategies for cardioprotection


DJ Hausenloy, DM Yellon - Diabetes, Obesity and Metabolism, 2008 - interscience.wiley.com
Despite optimal therapy, the morbidity and mortality of coronary heart disease
(CHD) remains significant, particularly in patients with diabetes or the
metabolic syndrome. New strategies for cardioprotection are therefore ...
Cited by 5 - Related articles - All 2 versions

Pharmacologic therapeutics for cardiac reperfusion injury


ER Gross, GJ Gross - Expert Opin. Emerging Drugs, 2007 - informahealthcare.com
Cardiovascular disease is the leading cause of morbidity and mortality in
industrial societies, with myocardial infarction as the primary assassin.
Pharmacologic agents, including the myocardial cell membrane receptor ...
Cited by 5 - Related articles - BL Direct - All 5 versions

Diabetes exacerbates angiographic coronary lesion progression in subjects with metabolic …


KW Liang, WJ Lee, WL Lee, YT Chen, CT … - Clinica Chimica Acta, 2007 - Elsevier
There were more cases of diabetes mellitus (52% vs. 31%, p = 0.040) in the CAD
progression group. The progression group also had higher baseline fasting blood
glucose (150 ± 73 vs. 117 ± 46 mg/dl, p = 0.010) but similar LDL ...
Cited by 4 - Related articles - All 2 versions

High-calorie-expenditure exercise: a new approach to cardiac rehabilitation for overweight …

- nursing2008.com
PA Ades, PD Savage, MJ Toth, J Harvey- … - Circulation, 2009 - Am Heart Assoc
Methods and Results— We performed a randomized controlled clinical trial to
evaluate the effect of high-calorie-expenditure exercise (3000- to 3500-kcal/wk
exercise-related energy expenditure) compared with standard CR exercise (7 ...
Cited by 3 - Related articles - All 7 versions

Economic impacts attributable to the early clinical benefit of atorvastatin therapy–a US …


RJ Straka, M Mamdani, J Damen, CEE Kuntze, … - Current Medical Research and Opinion®, 2007 - informahealthcare.com
Objective: The clinical literature suggests that atorvastatin therapy achieves a
reduction in major cardiovascular events within the first year of therapy. Aside
from obvious clinical benefits, economic advantage may also result from ...
Cited by 4 - Related articles - BL Direct - All 6 versions

[CITATION] What's in the CARDS?


CJ Plummer - Diabetic medicine, 2006 - cat.inist.fr
What's in the CARDS? CJ PLUMMER Diabetic medicine 23:77, 711-714, Blackwell, 2006.
Cited by 2 - Related articles - All 3 versions


Result Page: 

1

2

3

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google